Zacks Investment Research on MSN

KRYS reports preliminary results for 2025, outlines 2026 objectives

Krystal Biotech, Inc. KRYS expects preliminary unaudited net product revenues of $106-$107 million from lead drug Vyjuvek in ...
News-Medical.Net on MSN

TAAR1 mutation impairs brain signaling in schizophrenia

A genetic mutation passed from mother to children in families affected by schizophrenia has now been shown to completely ...